Previous close | 781,000.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 64,361 |
Market cap | 55.587T |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T (KRX: 028260.KS), and managed by Samsung Ventures, and BrickBio, Inc. announced Samsung's investment in BrickBio, a preclinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code.
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project (CDP).